Literature DB >> 33508385

Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.

Jennifer R Bourn1, Sasha J Ruiz-Torres1, Brian G Hunt1, Nancy M Benight1, Susan E Waltz2.   

Abstract

Increasing evidence suggests that cancer cells require both alterations in intrinsic cellular processes and the tumor microenvironment for tumor establishment, growth, and progression to metastatic disease. Despite this, knowledge of tumor-cell intrinsic molecular mechanisms controlling both tumor cell processes as well as the tumor microenvironment is limited. In this study, we provide evidence demonstrating the novel role of RON signaling in regulating breast cancer initiation, progression, and metastasis through modulation of tumor cell intrinsic processes and the tumor microenvironment. Using clinically relevant models of breast cancer, we show that RON signaling in the mammary epithelial tumor cells promotes tumor cell survival and proliferation as well as an immunopermissive microenvironment associated with decreased M1 macrophage, natural killer (NK) cell, and CD8+ T cell recruitment. Moreover, we demonstrate that RON signaling supports these phenotypes through novel mechanisms involving suppression of IRAK4 signaling and inhibition of type I Interferons. Our studies indicate that activation of RON signaling within breast cancer cells promotes tumor cell intrinsic growth and immune evasion which support breast cancer progression and highlight the role of targeting RON signaling as a potential therapeutic strategy against breast cancer.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; IRAK4 regulation; Receptor tyrosine kinases; Tumor microenvironment; Type I IFN signaling

Mesh:

Substances:

Year:  2021        PMID: 33508385      PMCID: PMC7981256          DOI: 10.1016/j.canlet.2021.01.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  75 in total

Review 1.  Type I interferons: crucial participants in disease amplification in autoimmunity.

Authors:  John C Hall; Antony Rosen
Journal:  Nat Rev Rheumatol       Date:  2010-01       Impact factor: 20.543

2.  Exogenous interferon and inducers of interferon in the treatment Balb-c mice inoculated with RC19 tumour cells.

Authors:  I Gresser; C Bourali
Journal:  Nature       Date:  1969-08-23       Impact factor: 49.962

3.  Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.

Authors:  Wen-Ying Lee; Helen H W Chen; Nan-Haw Chow; Wu-Chou Su; Pin-Wen Lin; How-Ran Guo
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

Review 4.  Cross-talk between tumor cells and the microenvironment at the metastatic niche.

Authors:  M J Carlini; M S De Lorenzo; L Puricelli
Journal:  Curr Pharm Biotechnol       Date:  2011-11       Impact factor: 2.837

Review 5.  What the Myddosome structure tells us about the initiation of innate immunity.

Authors:  Nicholas J Gay; Monique Gangloff; Luke A J O'Neill
Journal:  Trends Immunol       Date:  2011-01-25       Impact factor: 16.687

6.  Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.

Authors:  M-H Wang; W Lee; Y-L Luo; M T Weis; H-P Yao
Journal:  J Pathol       Date:  2007-12       Impact factor: 7.996

Review 7.  Crosstalk between cancer cells and endothelial cells: implications for tumor progression and intervention.

Authors:  Hyojeong Choi; Aree Moon
Journal:  Arch Pharm Res       Date:  2018-06-30       Impact factor: 4.946

8.  NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.

Authors:  Giulia Fregni; Aurélie Perier; Marie-Françoise Avril; Anne Caignard
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

9.  HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.

Authors:  Sasha J Ruiz-Torres; Nancy M Benight; Rebekah A Karns; Elyse E Lower; Jun-Lin Guan; Susan E Waltz
Journal:  Oncotarget       Date:  2017-07-22

Review 10.  Tuning cancer fate: the unremitting role of host immunity.

Authors:  B Calì; B Molon; A Viola
Journal:  Open Biol       Date:  2017-04       Impact factor: 6.411

View more
  5 in total

1.  RON (MST1R) and HGFL (MST1) Co-Overexpression Supports Breast Tumorigenesis through Autocrine and Paracrine Cellular Crosstalk.

Authors:  Brian G Hunt; Angelle Jones; Carissa Lester; James C Davis; Nancy M Benight; Susan E Waltz
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

2.  RON Mediates Tumor-Promoting Effects in Endometrial Adenocarcinoma.

Authors:  Qin Yu; Jianzhang Wang; Tiantian Li; Xinxin Xu; Xinyue Guo; Shaojie Ding; Libo Zhu; Gen Zou; Yichen Chen; Xinmei Zhang
Journal:  Biomed Res Int       Date:  2021-10-19       Impact factor: 3.411

3.  MicroRNA Expression Profiling of Lung Cancer with Differential Expression of the RON Receptor Tyrosine Kinase.

Authors:  Huilin Ou; Keda Chen; Hongcheng Wu
Journal:  J Oncol       Date:  2021-09-24       Impact factor: 4.375

4.  RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications.

Authors:  Abeer M Abdelbary; Randa Mohamed Kaf; Mohamed Elbakry Lashin; Ahmed Z Alattar; Dalia Hamouda Elsayed; Ahmed F Amin; Loay M Gertallah; Ahmed Mohamed Yehia
Journal:  Contemp Oncol (Pozn)       Date:  2022-06-30

5.  NMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival.

Authors:  Sara Vicente-Muñoz; Brian G Hunt; Taylor E Lange; Susanne I Wells; Susan E Waltz
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.